Stocktoria
PRECISION BIOSCIENCES INC DTIL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-03-28
PRECISION BIOSCIENCES INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M |
| R&D expense | $54.2M | $59.6M | $53.4M | $46.1M | $115.2M |
| Operating income | -$52.1M | -$26.2M | -$43.7M | -$62.3M | -$39.4M |
| Interest expense | — | $1.8M | $2.2M | $1.1M | $132,000 |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$45.7M | $7.2M | -$61.3M | -$111.6M | -$30.6M |
| EPS (diluted) | $-3.56 | $1.04 | $-15.96 | $-38.10 | $-0.52 |
| Operating cash flow | -$65.8M | -$58.4M | -$84.1M | -$45.8M | -$10.9M |
| Cash & equivalents | $110.8M | $85.9M | $116.7M | $189.6M | $143.7M |
| Total assets | $154.4M | $136.4M | $159.8M | $238.2M | $211.5M |
| Total liabilities | $62.2M | $80.0M | $140.9M | $177.7M | $120.3M |
| Shareholders' equity | $92.2M | $56.4M | $18.9M | $60.4M | $91.2M |
Source: SEC EDGAR filings · CIK 0001357874 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.